1380308-20-2

Upstream product

• 101080-03-9 1-chloro-4-methoxy-2-methyl-5-nitro-benzene 
• 1360616-09-6 (2-chloro-5-methoxy-4-nitro-phenyl)-methanol 

Downstream Products

• 1380308-19-9 (2-chloro-5-methoxy-4 nitrobenzyl)-phosphonic acid diethylester 
• 1380308-17-7 2-chloro-[4-(4-chloro-5-trifluoromethyl-pyrimidin-2-ylamino)-5-methoxy-benzyl]-phosphonic acid diethyl ester 
• 1380308-18-8 (4-amino-2-chloro-5-methoxy-benzyl)-phosphonic acid diethylester 

Relevant academic research and scientific papers

NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS

The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

MACROCYCLIC KINASE INHIBITORS

Compounds of Formula (I): wherein variables are defined herein, and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers for which FAK inhibition is beneficial.